Barely Significant
← all excerpts

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Blood Cancer J · 2022 · PMC9021312 · PMID 35443743

1
hedged sentence
closest p
boldest claim

The sentences

borderline significantno p-value reported
We also performed multivariable analysis, but only borderline significant values were observed for the on-TKI duration and presence of mutations at diagnosis (Supplemental Table 3 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.